Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Terminated 1Recruiting 1Completed 1Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Myeloid 1

Conditions

Hematologic Neoplasms 4Solid Tumor 1Primary Myelofibrosis 1Neoplasms 1Myeloproliferative Disorders 1

Interventions

fludarabine phosphate 38Cyclophosphamide 37Peripheral Blood Stem Cell Transplantation 32Busulfan 28Tacrolimus 26Whole-Body Irradiation 20Mycophenolic Acid 19Methotrexate 17Antilymphocyte Serum 17ruxolitinib 16fludarabine 14Filgrastim 13Cyclosporine 12Melphalan 11Radiotherapy 9Etoposide 9thymoglobulin 8Psychiatric Rehabilitation 8Prednisone 8Methylprednisolone 8Cytarabine 6Cord Blood Stem Cell Transplantation 6Thiotepa 5Sirolimus 5Imatinib Mesylate 5Flow Cytometry 5Azacitidine 5Alemtuzumab 5sargramostim 4merphos 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Primary Myelofibrosis × fedratinib × Clear all
NCT03952039 2025-08-28

FREEDOM2

Celgene

Phase 3 Completed
202 enrolled 23 charts
Myeloid

Myeloproliferative Disorders, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡